Aeolus Pharmaceuticals, Inc. (AOLS)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Aeolus Pharmaceuticals, Inc. (AOLS) with AI Score 47/100 (Weak). Aeolus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing novel compounds for biodefense and various diseases. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 17, 2026Aeolus Pharmaceuticals, Inc. (AOLS) Healthcare & Pipeline Overview
Aeolus Pharmaceuticals, Inc. is a biopharmaceutical firm specializing in catalytic antioxidant compounds for biodefense and diseases like fibrosis, oncology, and CNS disorders. Their lead asset, AEOL 10150, addresses acute radiation syndrome, positioning them within a niche market of medical countermeasures and targeted therapies.
Investment Thesis
Aeolus Pharmaceuticals operates in a high-risk, high-reward sector, focusing on biodefense and niche disease treatments. The company's lead compound, AEOL 10150, targeting acute radiation syndrome, represents a significant potential value driver, contingent on successful clinical trials and regulatory approval. Further development of AEOL 11114B, AEOL 11203, and AEOL 11207 for Parkinson's disease, and AEOL 20415 for infectious diseases, could diversify the pipeline. However, the company's negative profit margin of -171.4% and gross margin of -38.8% highlight financial challenges. The company's small size and OTC listing also present liquidity and volatility risks. Investors should closely monitor clinical trial outcomes, regulatory milestones, and funding activities.
Based on FMP financials and quantitative analysis
Key Highlights
- Aeolus Pharmaceuticals operates with a small team of 4 employees, indicating a lean operational structure.
- The company's lead compound, AEOL 10150, has completed two Phase I clinical trials, marking progress in its development as a medical countermeasure.
- Aeolus Pharmaceuticals is developing compounds for Parkinson's disease (AEOL 11114B, AEOL 11203, and AEOL 11207) and infectious diseases (AEOL 20415), expanding its therapeutic focus.
- The company's negative profit margin of -171.4% reflects significant expenses relative to revenue, typical for early-stage biopharmaceutical companies.
- Aeolus Pharmaceuticals has a negative Beta of -5.55, suggesting an inverse correlation with the market, although this may be less reliable due to its OTC status and limited trading volume.
Competitors & Peers
Strengths
- Proprietary platform of catalytic antioxidant compounds
- Lead compound (AEOL 10150) with completed Phase I clinical trials
- Focus on biodefense and niche disease treatments
- Potential for government contracts and partnerships
Weaknesses
- Negative profit and gross margins
- Limited financial resources
- Small team and operational scale
- OTC listing with associated liquidity risks
Catalysts
- Ongoing: Clinical trial progress for AEOL 10150 in treating acute radiation syndrome.
- Ongoing: Development of AEOL 11114B, AEOL 11203, and AEOL 11207 for Parkinson's disease.
- Ongoing: Advancement of AEOL 20415 for treating infectious diseases.
- Upcoming: Potential government contracts for biodefense medical countermeasures.
- Upcoming: Strategic partnerships with larger pharmaceutical companies.
Risks
- Ongoing: Negative profit and gross margins indicating financial instability.
- Potential: Clinical trial failures leading to loss of investment.
- Potential: Regulatory hurdles and delays in drug approval processes.
- Ongoing: Competition from larger pharmaceutical companies with greater resources.
- Potential: Funding challenges and potential for dilution of existing shareholders.
Growth Opportunities
- Development of AEOL 10150 for Acute Radiation Syndrome: The global market for medical countermeasures against radiation exposure is projected to grow, driven by increasing concerns over nuclear threats and accidents. Successful completion of clinical trials and regulatory approval for AEOL 10150 could provide Aeolus with a significant revenue stream. The timeline for this growth opportunity depends on the progress of clinical trials and regulatory review, potentially spanning several years.
- Expansion into Parkinson's Disease Treatment: The market for Parkinson's disease therapeutics is substantial and growing, driven by an aging population. Aeolus' development of AEOL 11114B, AEOL 11203, and AEOL 11207 represents an opportunity to tap into this market. Success in clinical trials and subsequent commercialization could lead to significant revenue growth. The timeline for this expansion depends on the progress of drug development and regulatory approvals.
- Advancement of AEOL 20415 for Infectious Diseases: The global market for infectious disease treatments is driven by the emergence of new pathogens and the increasing prevalence of existing infections. Aeolus' development of AEOL 20415 provides an opportunity to address unmet needs in this market. Successful development and commercialization could lead to revenue growth. The timeline for this opportunity depends on clinical trial outcomes and regulatory approvals.
- Strategic Partnerships and Collaborations: Aeolus could pursue strategic partnerships with larger pharmaceutical companies or government agencies to accelerate the development and commercialization of its drug candidates. Such partnerships could provide access to funding, expertise, and distribution channels, enhancing the company's growth prospects. The timeline for securing such partnerships is uncertain and depends on the attractiveness of Aeolus' pipeline and the willingness of potential partners.
- Government Contracts for Biodefense: Given its focus on medical countermeasures, Aeolus could pursue government contracts for the development and supply of drugs to protect against nuclear, radiological, and chemical threats. Securing such contracts could provide a stable revenue stream and validate the company's technology. The timeline for securing government contracts depends on government priorities and procurement processes.
Opportunities
- Advancement of AEOL 10150 through clinical trials and regulatory approval
- Expansion into Parkinson's disease and infectious disease treatments
- Strategic partnerships with larger pharmaceutical companies
- Government contracts for biodefense
Threats
- Clinical trial failures
- Regulatory hurdles and delays
- Competition from larger pharmaceutical companies
- Funding challenges and dilution
Competitive Advantages
- Proprietary platform of catalytic antioxidant compounds.
- Patents protecting drug candidates and technologies.
- Expertise in developing medical countermeasures.
- Specialized focus on niche disease treatments.
About AOLS
Founded in 1994 and based in Mission Viejo, California, Aeolus Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing a platform of novel compounds. The company's primary focus is on creating medical countermeasures against nuclear, radiological, and chemical weapons, as well as treatments for diseases and disorders affecting the respiratory system, central nervous system, and oncology. Their lead compound, AEOL 10150, has completed two Phase I clinical trials and is being developed to combat the pulmonary sub-syndrome of acute radiation syndrome. It is also intended for use as a medical countermeasure against exposure to chemical vesicants and nerve agents. In addition to AEOL 10150, Aeolus is developing AEOL 11114B, AEOL 11203, and AEOL 11207 for the treatment of Parkinson's disease, and AEOL 20415 for treating infectious diseases. Aeolus Pharmaceuticals operates primarily in the United States, focusing on specialized drug development within the biodefense and targeted therapy sectors. The company aims to address unmet medical needs through its innovative platform of catalytic antioxidant compounds.
What They Do
- Develop catalytic antioxidant compounds for medical countermeasures.
- Create treatments for acute radiation syndrome.
- Develop drugs for exposure to chemical vesicants and nerve agents.
- Research treatments for diseases of the respiratory system.
- Develop therapies for central nervous system disorders.
- Develop oncology treatments.
- Research treatments for Parkinson's disease.
- Develop therapies for infectious diseases.
Business Model
- Develop novel pharmaceutical compounds.
- Conduct preclinical and clinical trials to evaluate drug safety and efficacy.
- Seek regulatory approval for drug candidates.
- Potentially commercialize approved drugs through partnerships or direct sales.
Industry Context
Aeolus Pharmaceuticals operates within the specialty and generic drug manufacturing industry, a segment characterized by intense competition and regulatory scrutiny. The market is driven by factors such as an aging population, increasing prevalence of chronic diseases, and advancements in drug development technologies. Companies like Aeolus face competition from larger pharmaceutical firms and other specialty drug developers. The industry is also subject to evolving regulatory landscapes, impacting drug approval processes and market access. Aeolus' focus on biodefense and niche disease treatments positions it within a specialized segment of this broader market.
Key Customers
- Government agencies responsible for biodefense.
- Hospitals and healthcare providers.
- Patients suffering from targeted diseases.
Financials
Chart & Info
Aeolus Pharmaceuticals, Inc. (AOLS) stock price: Price data unavailable
Latest News
No recent news available for AOLS.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for AOLS.
Price Targets
Wall Street price target analysis for AOLS.
MoonshotScore
What does this score mean?
The MoonshotScore rates AOLS's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Christopher Stanley
CEO
Christopher Stanley serves as the CEO of Aeolus Pharmaceuticals, Inc. His background includes experience in managing and leading small teams within the biopharmaceutical sector. He has been involved in the strategic direction of the company, overseeing the development of its pipeline of novel compounds. His expertise lies in guiding the company through the various stages of drug development, from preclinical research to clinical trials.
Track Record: Under Christopher Stanley's leadership, Aeolus Pharmaceuticals has focused on advancing its lead compound, AEOL 10150, through clinical trials. He has also overseen the development of other compounds targeting Parkinson's disease and infectious diseases. His tenure has been marked by efforts to secure funding and partnerships to support the company's research and development activities.
AOLS OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Aeolus Pharmaceuticals may not meet the minimum financial or disclosure requirements of the higher tiers (OTCQX and OTCQB). Companies in this tier often have limited operating history, may be thinly traded, and may not be subject to the same level of regulatory scrutiny as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries significant risks due to the potential for fraud, lack of transparency, and limited liquidity.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency
- Potential for fraud or manipulation
- Thin trading volume and wide bid-ask spreads
- Higher price volatility
- Limited regulatory oversight
- Verify the company's legal status and registration.
- Obtain and review any available financial statements.
- Assess the company's management team and their experience.
- Research the company's products and market potential.
- Evaluate the company's competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Consult with a qualified financial advisor.
- Completion of Phase I clinical trials for AEOL 10150
- Development of compounds for Parkinson's disease and infectious diseases
- Focus on biodefense and medical countermeasures
- Company has been in business since 1994
What Investors Ask About Aeolus Pharmaceuticals, Inc. (AOLS)
What does Aeolus Pharmaceuticals, Inc. do?
Aeolus Pharmaceuticals, Inc. is a biopharmaceutical company that develops a platform of novel catalytic antioxidant compounds. These compounds are designed for use in biodefense, specifically as medical countermeasures against nuclear, radiological, and chemical weapons. Additionally, they are being developed for the treatment of diseases and disorders of the respiratory system, central nervous system, and oncology. The company's lead compound, AEOL 10150, targets acute radiation syndrome and chemical weapon exposure.
What do analysts say about AOLS stock?
AI analysis is currently pending for AOLS. Given Aeolus Pharmaceutical's OTC listing and small market capitalization, formal analyst coverage may be limited. Investors should conduct their own due diligence, focusing on clinical trial progress, regulatory milestones, and financial stability. Key valuation metrics are difficult to assess due to the company's early stage and negative profitability. Growth considerations depend heavily on the successful development and commercialization of its drug candidates.
What are the main risks for AOLS?
The main risks for Aeolus Pharmaceuticals, Inc. include the inherent uncertainties of drug development, such as clinical trial failures and regulatory hurdles. The company's limited financial resources and negative profit margins pose a significant risk to its ability to fund ongoing research and development. Competition from larger pharmaceutical companies with greater resources is also a major concern. Additionally, the company's OTC listing exposes it to liquidity risks and potential price volatility.
What are the key factors to evaluate for AOLS?
Aeolus Pharmaceuticals, Inc. (AOLS) currently holds an AI score of 47/100, indicating low score. Key strength: Proprietary platform of catalytic antioxidant compounds. Primary risk to monitor: Ongoing: Negative profit and gross margins indicating financial instability.. This is not financial advice.
How frequently does AOLS data refresh on this page?
AOLS prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven AOLS's recent stock price performance?
Recent price movement in Aeolus Pharmaceuticals, Inc. (AOLS) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary platform of catalytic antioxidant compounds. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider AOLS overvalued or undervalued right now?
Determining whether Aeolus Pharmaceuticals, Inc. (AOLS) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying AOLS?
Before investing in Aeolus Pharmaceuticals, Inc. (AOLS), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be less reliable than data from major exchanges.